zurück

Tixagevimab / cilgavimab (obligation for benefit assessment for the first time: COVID-19; patients not requiring supplemental oxygen; patients aged ≥ 12 years)

 

Subject:

  • Active Substance: Tixagevimab / cilgavimab
  • Name: Evusheld®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: AstraZeneca GmbH

 

Time table:

  • Start: 15.10.2022
  • Final decision by G-BA: 20.04.2023

 

Final decision:

  1. Adult patients with infection with a viral variant against which tixagevimab / cilgavimab does not show sufficient efficacy: No additional benefit proved
  2. Adult patients with infection with a viral variant against which tixagevimab / cilgavimab shows sufficient efficacy: Hint for a minor additional benefit

  3. Adolescents 12 years of age or older with a body weight of at least 40 kg: No additional benefit proved